Institute for Asthma and Allergy, Chevy Chase and Wheaton, Maryland, and George Washington University School of Medicine, Washington, DC, USA.
Ann Allergy Asthma Immunol. 2011 Feb;106(2 Suppl):S6-S11. doi: 10.1016/j.anai.2010.08.010.
To discuss the new use of intranasal antihistamines as first-line therapies, compare and contrast this class of medication with the traditionally available medications, and discuss the potential for intranasal antihistamines to provide relief superior to second-generation oral antihistamines.
Review articles and original research articles were retrieved from MEDLINE, OVID, PubMed (1950 to November 2009), personal files of articles, and bibliographies of located articles that addressed the topic of interest.
Articles were selected for their relevance to intranasal antihistamines and their role in allergic rhinitis. Publications included reviews, treatment guidelines, and clinical studies (primarily randomized controlled trials) of both children and adults.
This panel was charged with reviewing the place of intranasal antihistamines in the spectrum of treatment for allergic rhinitis. Intranasal antihistamines have been shown in numerous randomized, placebo-controlled trials to be more efficacious than the oral antihistamines. Although intranasal corticosteroids are considered by some to be superior to intranasal antihistamines, multiple studies have shown an equal effect of the 2 classes of medication. Both intranasal corticosteroids and intranasal antihistamines have been shown to reduce all symptoms of allergic rhinitis. In addition, some intranasal antihistamines have a more rapid onset of action than intranasal corticosteroids.
The future of allergy treatment will likely involve a combination of both intranasal corticosteroids and intranasal antihistamines because of the benefits of local administration and their additive effect on efficacy.
讨论将鼻内抗组胺药作为一线治疗药物的新用途,比较和对比此类药物与传统可用药物,并讨论鼻内抗组胺药提供优于第二代口服抗组胺药的缓解的潜力。
从 MEDLINE、OVID、PubMed(1950 年至 2009 年 11 月)、文章的个人档案和找到的文章的参考文献中检索了评论文章和原始研究文章,这些文章涉及感兴趣的主题。
选择的文章与鼻内抗组胺药及其在过敏性鼻炎中的作用相关。出版物包括评论、治疗指南和儿童和成人的临床研究(主要是随机对照试验)。
该小组负责审查鼻内抗组胺药在过敏性鼻炎治疗谱中的地位。大量随机、安慰剂对照试验表明,鼻内抗组胺药比口服抗组胺药更有效。虽然一些人认为鼻内皮质类固醇优于鼻内抗组胺药,但多项研究表明这 2 类药物的效果相等。鼻内皮质类固醇和鼻内抗组胺药均已被证明可减轻过敏性鼻炎的所有症状。此外,一些鼻内抗组胺药的作用比鼻内皮质类固醇更快。
由于局部给药的益处及其对疗效的附加作用,过敏治疗的未来可能涉及鼻内皮质类固醇和鼻内抗组胺药的联合使用。